BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 545 filers reported holding BIO-TECHNE CORP in Q1 2024. The put-call ratio across all filers is 1.05 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2024 | $1,238,864 | -8.8% | 17,600 | 0.0% | 0.01% | -22.2% |
Q4 2023 | $1,358,016 | -84.6% | 17,600 | -86.4% | 0.01% | -86.2% |
Q3 2023 | $8,817,056 | -13.2% | 129,529 | -5.4% | 0.06% | +4.8% |
Q1 2023 | $10,161,827 | +424.9% | 136,970 | +486.3% | 0.06% | +463.6% |
Q4 2022 | $1,936,077 | -82.2% | 23,360 | -38.9% | 0.01% | -82.0% |
Q3 2022 | $10,858,000 | +19.4% | 38,232 | +45.8% | 0.06% | +8.9% |
Q2 2022 | $9,092,000 | +109.8% | 26,230 | +162.1% | 0.06% | +51.4% |
Q1 2022 | $4,333,000 | -20.0% | 10,006 | -4.4% | 0.04% | -28.8% |
Q4 2021 | $5,417,000 | -38.6% | 10,470 | -42.5% | 0.05% | -53.2% |
Q3 2021 | $8,821,000 | -12.2% | 18,204 | -18.4% | 0.11% | -1.8% |
Q2 2021 | $10,047,000 | +4287.3% | 22,313 | +3618.8% | 0.11% | +3666.7% |
Q1 2021 | $229,000 | -95.5% | 600 | -96.3% | 0.00% | -95.8% |
Q4 2020 | $5,139,000 | +376.3% | 16,184 | +271.7% | 0.07% | +343.8% |
Q3 2020 | $1,079,000 | +84.8% | 4,354 | +97.0% | 0.02% | +60.0% |
Q2 2020 | $584,000 | +12.5% | 2,210 | -19.3% | 0.01% | -28.6% |
Q1 2020 | $519,000 | +95.1% | 2,739 | +126.2% | 0.01% | +180.0% |
Q4 2019 | $266,000 | +118.0% | 1,211 | +94.1% | 0.01% | +150.0% |
Q3 2019 | $122,000 | -97.0% | 624 | -96.8% | 0.00% | -97.3% |
Q2 2019 | $4,058,000 | +1093.5% | 19,465 | +1037.0% | 0.08% | +581.8% |
Q1 2019 | $340,000 | -74.1% | 1,712 | -80.7% | 0.01% | -83.3% |
Q2 2018 | $1,313,000 | +129.5% | 8,873 | +134.1% | 0.07% | +100.0% |
Q1 2018 | $572,000 | +46.7% | 3,790 | +17.5% | 0.03% | +50.0% |
Q3 2017 | $390,000 | +222.3% | 3,226 | +192.5% | 0.02% | +175.0% |
Q3 2016 | $121,000 | -40.7% | 1,103 | -50.1% | 0.01% | -27.3% |
Q4 2014 | $204,000 | – | 2,212 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Blue Water Life Science Advisors, LP | 54,711 | $28,304,000 | 8.66% |
Montanaro Asset Management Ltd | 104,450 | $54,036,000 | 5.45% |
Ownership Capital B.V. | 891,186 | $461,046,000 | 4.99% |
Sandhill Capital Partners LLC | 121,682 | $62,951,000 | 4.89% |
Brown Capital Management | 986,803 | $510,513,000 | 4.22% |
STONE RUN CAPITAL, LLC | 22,300 | $11,536,000 | 3.73% |
DF DENT & CO INC | 681,416 | $352,524,000 | 3.54% |
MAIRS & POWER INC | 653,815 | $338,244,000 | 3.13% |
Summit Creek Advisors LLC | 57,959 | $29,985,000 | 3.01% |
Aristotle Atlantic Partners, LLC | 95,597 | $49,456,000 | 2.87% |